UY33772A - Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma. - Google Patents

Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma.

Info

Publication number
UY33772A
UY33772A UY0001033772A UY33772A UY33772A UY 33772 A UY33772 A UY 33772A UY 0001033772 A UY0001033772 A UY 0001033772A UY 33772 A UY33772 A UY 33772A UY 33772 A UY33772 A UY 33772A
Authority
UY
Uruguay
Prior art keywords
valsartan
pharmaceutical composition
preparation
lercanidipine
active components
Prior art date
Application number
UY0001033772A
Other languages
English (en)
Inventor
Chung Young Sik
Park Soo Ah
Kim Ree Sun
Kim Sung Il
Juhn Jae Hyeon
Kim Dong Kyu
Kim Yoo Rin
Park Hee Dong
Park Seong Jae
Lee Sung Hack
Kim Ju Hyun
Jung Min Young
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33772(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of UY33772A publication Critical patent/UY33772A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparación de la misma. La composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán de acuerdo con la presente invención tiene un efecto superior en la prevención y el tratamiento de cardiovasculopatías y sus enfermedades complejas, y reduce los efectos adversos de cada componente. Además, la presente composición comprende clorhidrato de lercanidipina y valsartán en forma separada, a fin de incrementar los índices de disolución de ambos componentes y reducir los efectos adversos.
UY0001033772A 2010-12-09 2011-12-06 Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma. UY33772A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09

Publications (1)

Publication Number Publication Date
UY33772A true UY33772A (es) 2012-07-31

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033772A UY33772A (es) 2010-12-09 2011-12-06 Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma.

Country Status (17)

Country Link
EP (1) EP2648730A4 (es)
KR (1) KR101414814B1 (es)
CN (1) CN103249415B (es)
AR (1) AR084195A1 (es)
AU (1) AU2011339150B2 (es)
BR (1) BR112013013415A2 (es)
CL (1) CL2013001626A1 (es)
CO (1) CO6721030A2 (es)
DO (1) DOP2013000115A (es)
EA (1) EA201390844A1 (es)
IL (1) IL226449A0 (es)
MX (1) MX2013005716A (es)
PE (1) PE20140699A1 (es)
SG (1) SG190326A1 (es)
UA (1) UA108277C2 (es)
UY (1) UY33772A (es)
WO (1) WO2012077968A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
EP2977048A4 (en) * 2013-03-12 2017-04-26 LG Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
KR101414814B1 (ko) 2014-07-21
AU2011339150B2 (en) 2015-09-10
EP2648730A2 (en) 2013-10-16
BR112013013415A2 (pt) 2019-09-24
SG190326A1 (en) 2013-06-28
EA201390844A1 (ru) 2013-11-29
PE20140699A1 (es) 2014-06-13
CN103249415B (zh) 2017-12-12
WO2012077968A3 (en) 2012-07-26
KR20120089787A (ko) 2012-08-13
CO6721030A2 (es) 2013-07-31
UA108277C2 (ru) 2015-04-10
IL226449A0 (en) 2013-07-31
MX2013005716A (es) 2013-06-12
CL2013001626A1 (es) 2013-10-04
WO2012077968A2 (en) 2012-06-14
DOP2013000115A (es) 2014-07-31
CN103249415A (zh) 2013-08-14
EP2648730A4 (en) 2014-08-06
AU2011339150A1 (en) 2013-06-06
AR084195A1 (es) 2013-04-24

Similar Documents

Publication Publication Date Title
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
ECSP12011585A (es) Compuestos y composiciones para eltratamiento de enfermedades parasitarias
EA201501024A1 (ru) Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
CL2013002134A1 (es) Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
GT201400261A (es) Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
BR112015011430A2 (pt) composição para liberação imediata e prolongada
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
DOP2013000115A (es) Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma
CO2018004665A2 (es) Compuestos oxadiazoespíricos
GT201400042A (es) Compuesto de benzotiazolona
CO7131356A2 (es) Método para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
SMT201600243B (it) Composizioni farmaceutiche comprendenti anakinra senza citrato
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
IL236562A0 (en) A pharmaceutical preparation with an improved flow capacity, a medical agent, and a method for its production and use
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
EA201400444A1 (ru) Производные 2-оксопиперидинила
UY33789A (es) Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab
IN2013MU03428A (es)
IN2014DN07897A (es)
BR112015003761A2 (pt) composto, composição farmacêutica, forma unitária de dosagem, método para administrar um agente biologicamente ativo e método para preparar uma composição
EA201200799A1 (ru) Гепатопротекторное средство

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200124